腫瘍随伴マクロファージ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "腫瘍随伴マクロファージ" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

1semanticscholar.org

11^th place

1,537^th place

1clinicaltrials.gov

5,225^th place

low place

low place

low place

low place

low place

clinicaltrials.gov

臨床試験番号 NCT03158272 研究名 "A Study to of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread" - ClinicalTrials.gov

doi.org

“Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy”. Advanced Drug Delivery Reviews 99 (Pt B): 180–185. (April 2016). doi:10.1016/j.addr.2015.11.009. PMID 26621196.
“Macrophages and cancer: from mechanisms to therapeutic implications”. Trends in Immunology 36 (4): 229–39. (April 2015). doi:10.1016/j.it.2015.02.004. PMID 25770924.
“Macrophage diversity enhances tumor progression and metastasis”. Cell 141 (1): 39–51. (April 2010). doi:10.1016/j.cell.2010.03.014. PMC 4994190. PMID 20371344.
“Tumour-associated macrophages as treatment targets in oncology”. Nature Reviews. Clinical Oncology 14 (7): 399–416. (July 2017). doi:10.1038/nrclinonc.2016.217. PMC 5480600. PMID 28117416.
“Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis”. Frontiers in Physiology 5: 75. (5 March 2014). doi:10.3389/fphys.2014.00075. PMC 3942647. PMID 24634660.
“Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis”. Nature Cell Biology 2 (10): 737–44. (October 2000). doi:10.1038/35036374. PMC 2852586. PMID 11025665.
“Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer”. Cancer Research 74 (11): 2962–73. (June 2014). doi:10.1158/0008-5472.CAN-13-2421. PMC 4137408. PMID 24638982.
“Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors”. Cancer Cell 8 (3): 211–26. (September 2005). doi:10.1016/j.ccr.2005.08.002. PMID 16169466.
“Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion”. Journal of Immunology 186 (7): 4183–90. (April 2011). doi:10.4049/jimmunol.1002802. PMID 21368233.
“Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer”. PLOS ONE 9 (6): e98623. (3 June 2014). doi:10.1371/journal.pone.0098623. PMC 4043882. PMID 24892425.
“Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms”. Life Sciences 92 (2): 101–7. (February 2013). doi:10.1016/j.lfs.2012.10.008. PMC 3740377. PMID 23178150.
“Crosstalk between angiogenesis and lymphangiogenesis in tumor progression”. Leukemia 18 (6): 1054–8. (June 2004). doi:10.1038/sj.leu.2403355. PMID 15057248.
“A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation)”. Blood 107 (5): 2112–22. (March 2006). doi:10.1182/blood-2005-01-0428. PMID 16269622.
“High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors”. The American Journal of Pathology 174 (3): 1048–64. (March 2009). doi:10.2353/ajpath.2009.080676. PMC 2665764. PMID 19218341.
“Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1”. The Journal of Experimental Medicine 206 (6): 1327–37. (June 2009). doi:10.1084/jem.20082173. PMC 2715058. PMID 19451266.
“B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma”. The Journal of Experimental Medicine 203 (4): 871–81. (April 2006). doi:10.1084/jem.20050930. PMC 2118300. PMID 16606666.
“Tumor-associated macrophages: from mechanisms to therapy”. Immunity 41 (1): 49–61. (July 2014). doi:10.1016/j.immuni.2014.06.010. PMC 4137410. PMID 25035953.
“Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression”. Cancer Research 70 (19): 7465–75. (October 2010). doi:10.1158/0008-5472.CAN-10-1439. PMC 2948598. PMID 20841473.
“Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy”. Nature Medicine 25 (4): 656–666. (April 2019). doi:10.1038/s41591-019-0374-x. PMC 7175920. PMID 30833750.
“The M1 and M2 paradigm of macrophage activation: time for reassessment”. F1000prime Reports 6: 13. (3 March 2014). doi:10.12703/P6-13. PMC 3944738. PMID 24669294.
“The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages”. Critical Reviews in Oncology/Hematology 66 (1): 1–9. (April 2008). doi:10.1016/j.critrevonc.2007.07.004. PMID 17913510.
“Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy”. NPJ Breast Cancer 2 (1). (2016-01-20). doi:10.1038/npjbcancer.2015.25. PMC 4794275. PMID 26998515.
“CSF-1R inhibition alters macrophage polarization and blocks glioma progression”. Nature Medicine 19 (10): 1264–72. (October 2013). doi:10.1038/nm.3337. PMC 3840724. PMID 24056773.
“Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy”. Journal for Immunotherapy of Cancer 5 (1): 53. (July 2017). doi:10.1186/s40425-017-0257-y. PMC 5514481. PMID 28716061.
Sankhala, Kamalesh Kumar; Blay, Jean-Yves; Ganjoo, Kristen N.; Italiano, Antoine; Hassan, Andrew Bassim; Kim, Tae Min; Ravi, Vinod; Cassier, Philippe Alexandre et al. (2017). “A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS)”. Journal of Clinical Oncology 35 (15_suppl): 11078. doi:10.1200/JCO.2017.35.15_suppl.11078.
“Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging”. Nature Communications 8: 14293. (February 2017). doi:10.1038/ncomms14293. PMC 5309815. PMID 28176769.
“TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy”. Nature Biomedical Engineering 2 (8): 578–588. (August 2018). doi:10.1038/s41551-018-0236-8. PMID 31015631.
“Macrophages and therapeutic resistance in cancer”. Cancer Cell 27 (4): 462–72. (April 2015). doi:10.1016/j.ccell.2015.02.015. PMC 4400235. PMID 25858805.
“Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages”. Nature 543 (7645): 428–432. (March 2017). doi:10.1038/nature21409. PMID 28273064.

nih.gov

pubmed.ncbi.nlm.nih.gov

“Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy”. Advanced Drug Delivery Reviews 99 (Pt B): 180–185. (April 2016). doi:10.1016/j.addr.2015.11.009. PMID 26621196.
“Macrophages and cancer: from mechanisms to therapeutic implications”. Trends in Immunology 36 (4): 229–39. (April 2015). doi:10.1016/j.it.2015.02.004. PMID 25770924.
“Macrophage diversity enhances tumor progression and metastasis”. Cell 141 (1): 39–51. (April 2010). doi:10.1016/j.cell.2010.03.014. PMC 4994190. PMID 20371344.
“Tumour-associated macrophages as treatment targets in oncology”. Nature Reviews. Clinical Oncology 14 (7): 399–416. (July 2017). doi:10.1038/nrclinonc.2016.217. PMC 5480600. PMID 28117416.
“Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis”. Frontiers in Physiology 5: 75. (5 March 2014). doi:10.3389/fphys.2014.00075. PMC 3942647. PMID 24634660.
“Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis”. Nature Cell Biology 2 (10): 737–44. (October 2000). doi:10.1038/35036374. PMC 2852586. PMID 11025665.
“Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer”. Cancer Research 74 (11): 2962–73. (June 2014). doi:10.1158/0008-5472.CAN-13-2421. PMC 4137408. PMID 24638982.
“Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors”. Cancer Cell 8 (3): 211–26. (September 2005). doi:10.1016/j.ccr.2005.08.002. PMID 16169466.
“Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion”. Journal of Immunology 186 (7): 4183–90. (April 2011). doi:10.4049/jimmunol.1002802. PMID 21368233.
“Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer”. PLOS ONE 9 (6): e98623. (3 June 2014). doi:10.1371/journal.pone.0098623. PMC 4043882. PMID 24892425.
“Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms”. Life Sciences 92 (2): 101–7. (February 2013). doi:10.1016/j.lfs.2012.10.008. PMC 3740377. PMID 23178150.
“Crosstalk between angiogenesis and lymphangiogenesis in tumor progression”. Leukemia 18 (6): 1054–8. (June 2004). doi:10.1038/sj.leu.2403355. PMID 15057248.
“A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation)”. Blood 107 (5): 2112–22. (March 2006). doi:10.1182/blood-2005-01-0428. PMID 16269622.
“High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors”. The American Journal of Pathology 174 (3): 1048–64. (March 2009). doi:10.2353/ajpath.2009.080676. PMC 2665764. PMID 19218341.
“Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1”. The Journal of Experimental Medicine 206 (6): 1327–37. (June 2009). doi:10.1084/jem.20082173. PMC 2715058. PMID 19451266.
“B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma”. The Journal of Experimental Medicine 203 (4): 871–81. (April 2006). doi:10.1084/jem.20050930. PMC 2118300. PMID 16606666.
“Tumor-associated macrophages: from mechanisms to therapy”. Immunity 41 (1): 49–61. (July 2014). doi:10.1016/j.immuni.2014.06.010. PMC 4137410. PMID 25035953.
“Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression”. Cancer Research 70 (19): 7465–75. (October 2010). doi:10.1158/0008-5472.CAN-10-1439. PMC 2948598. PMID 20841473.
“Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy”. Nature Medicine 25 (4): 656–666. (April 2019). doi:10.1038/s41591-019-0374-x. PMC 7175920. PMID 30833750.
“The M1 and M2 paradigm of macrophage activation: time for reassessment”. F1000prime Reports 6: 13. (3 March 2014). doi:10.12703/P6-13. PMC 3944738. PMID 24669294.
“The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages”. Critical Reviews in Oncology/Hematology 66 (1): 1–9. (April 2008). doi:10.1016/j.critrevonc.2007.07.004. PMID 17913510.
“Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy”. NPJ Breast Cancer 2 (1). (2016-01-20). doi:10.1038/npjbcancer.2015.25. PMC 4794275. PMID 26998515.
“CSF-1R inhibition alters macrophage polarization and blocks glioma progression”. Nature Medicine 19 (10): 1264–72. (October 2013). doi:10.1038/nm.3337. PMC 3840724. PMID 24056773.
“Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy”. Journal for Immunotherapy of Cancer 5 (1): 53. (July 2017). doi:10.1186/s40425-017-0257-y. PMC 5514481. PMID 28716061.
“Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging”. Nature Communications 8: 14293. (February 2017). doi:10.1038/ncomms14293. PMC 5309815. PMID 28176769.
“TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy”. Nature Biomedical Engineering 2 (8): 578–588. (August 2018). doi:10.1038/s41551-018-0236-8. PMID 31015631.
“Macrophages and therapeutic resistance in cancer”. Cancer Cell 27 (4): 462–72. (April 2015). doi:10.1016/j.ccell.2015.02.015. PMC 4400235. PMID 25858805.
“Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages”. Nature 543 (7645): 428–432. (March 2017). doi:10.1038/nature21409. PMID 28273064.

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

onclive.com

Inman (12 November 2017). “Novel Combination Shows Promising Responses in Pancreatic Cancer”. OncLive. 2022年4月10日閲覧。

semanticscholar.org

“A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation)”. Blood 107 (5): 2112–22. (March 2006). doi:10.1182/blood-2005-01-0428. PMID 16269622.

wikipedia.org

en.wikipedia.org

臨床試験番号 NCT03158272 研究名 "A Study to of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread" - ClinicalTrials.gov